Pfizer’s monthly berobenatide hit nausea-and-vomiting rates close to Wegovy’s mid-stage benchmark
The side-effect profile of a new monthly GLP-1 rival lands near Novo Nordisk’s weekly target, sharpening the obesity race.
By Khalid Al-Harbi·· 4 min
1 briefing · “benchmarks”
The side-effect profile of a new monthly GLP-1 rival lands near Novo Nordisk’s weekly target, sharpening the obesity race.